Transfusion medicine (Oxford, England) · 2026
Implementation of BSH 2020 irradiation guidelines for children with DiGeorge syndrome.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Firth Oliver, Arnold Philip, Gennery Andrew R, Johnson Robert, Mele Sara, Shackleton Tracey, Grant-Casey John, Foukaneli Theodora, New Helen V
Аннотация
BACKGROUND: Transfusion-associated graft-versus-host disease (Ta-GvHD) is a rare, usually fatal complication of transfusing cellular components, prevented by irradiation. Congenital heart disease (CHD), particularly DiGeorge syndrome (del22q), may be associated with severe T-cell immunodeficiency and Ta-GvHD risk. British Society for Haematology guidelines (BSH, 2020) recommended targeted use of irradiated components for CHD based on immunological assessment; guideline adherence was unknown.
OBJECTIVES: To understand UK use of irradiated components for paediatric CHD surgery and barriers to BSH guideline implementation.
METHODS: An electronic survey distributed to the 11 UK paediatric cardiothoracic surgical centres (January-March 2024 inclusive).
RESULTS: Of the 11 centres, 9 (82%) responded. Naïve T-cell enumeration, the BSH recommended test, was available to 8/9 (89%), but used in 4/9 (44%). 4/9 (44%) and 5/9 (56%) centres were willing to provide non-irradiated components to neonates and children >28 days of age. Of these, 1/4 (25%), 1/5 (20%), and 4/5 (80%) (for neonates, young children, and children from 2 years) required criteria additional to BSH guidelines. 8/9 (89%) centres reported ongoing barriers to guideline implementation, particularly challenges around pathway development and timely naïve T-cell enumeration.
CONCLUSION: Overuse of irradiated components in surgery for patients with congenital heart disease is high: only 1/3 of paediatric cardiac centres adhered to BSH guidance. Reasons included difficulties in immunological diagnostic pathway development. Collaboration between paediatric cardiothoracic, transfusion and immunology teams is required to address this.
OBJECTIVES: To understand UK use of irradiated components for paediatric CHD surgery and barriers to BSH guideline implementation.
METHODS: An electronic survey distributed to the 11 UK paediatric cardiothoracic surgical centres (January-March 2024 inclusive).
RESULTS: Of the 11 centres, 9 (82%) responded. Naïve T-cell enumeration, the BSH recommended test, was available to 8/9 (89%), but used in 4/9 (44%). 4/9 (44%) and 5/9 (56%) centres were willing to provide non-irradiated components to neonates and children >28 days of age. Of these, 1/4 (25%), 1/5 (20%), and 4/5 (80%) (for neonates, young children, and children from 2 years) required criteria additional to BSH guidelines. 8/9 (89%) centres reported ongoing barriers to guideline implementation, particularly challenges around pathway development and timely naïve T-cell enumeration.
CONCLUSION: Overuse of irradiated components in surgery for patients with congenital heart disease is high: only 1/3 of paediatric cardiac centres adhered to BSH guidance. Reasons included difficulties in immunological diagnostic pathway development. Collaboration between paediatric cardiothoracic, transfusion and immunology teams is required to address this.